HSA Updates
HSA Approves "Spikevax" as the New Brand Name for Moderna's COVID-19 Vaccine
Audiences
Consumer
Healthcare professional
Industry member
Product type
Therapeutic Products
14 September 2021
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
The Health Sciences Authority (HSA) has on 14 September 2021 approved the application by Moderna to introduce the brand name “Spikevax” for its COVID-19 vaccine currently authorised under the Pandemic Special Access Route. There are no changes to the vaccine and its quality, safety and efficacy.
HEALTH SCIENCES AUTHORITY
SINGAPORE
14 SEPTEMBER 2021